Oxurion announces its software strategy with Exagis

The Leuven-based biopharmaceutical company Oxurion is launching a software-driven growth strategy, highlighting Exagis, its clinical data management platform. Initially developed to manage internal trial data, Exagis is now expanding to a broader market, integrating more than 16,000 patients and 600 clinical centers.

Recent developments have enabled Exagis to be marketed independently, generating separate software revenue for Oxurion. This platform captures operational experience, enriching its software ecosystem, which will soon be complemented by an eTMF module scheduled for July 2026.

Oxurion also plans to integrate artificial intelligence capabilities to optimize efficiency and compliance in clinical research. The goal is to strengthen its position as a robust and scalable technology platform.